Child and Adolescent Psychiatry and Mental Health (Jul 2024)

Randomized, double-blind, placebo-controlled trial of aripiprazole oral solution in children and adolescents with Tourette’s disorder

  • Fan He,
  • Jie Luo,
  • Yi Huang,
  • Yunpeng Hao,
  • Ling Sun,
  • Xiaoyan Ke,
  • Bin Wu,
  • Yucai Chen,
  • Ying Han,
  • Yuebing Zhang,
  • Jing Liu,
  • Hong Han,
  • Mingji Xian,
  • Motomichi Uki,
  • Yi Zheng

DOI
https://doi.org/10.1186/s13034-024-00764-6
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Background Aripiprazole is the most frequently recommended antipsychotic for the treatment of tics in children and adolescents with Tourette’s disorder (TD). However, to date, a randomized controlled trial for aripiprazole oral solution has not been conducted despite being widely preferred by children. Therefore, we examined whether aripiprazole oral solution is effective for treating tics. Methods All patients received a flexible dose of aripiprazole oral solution (1 mg/mL, range: 2–20 mg) with a starting dose of 2 mg. The target dose for patients weighing < 50 kg was 2, 5, and 10 mg/day, and that for patients weighing ≥ 50 kg was 5, 10, 15, and 20 mg/day. The primary efficacy endpoint was the mean change in the Yale Global Tic Severity Scale-total tic score (YGTSS-TTS) from baseline to week 8. Results Of the 121 patients enrolled, 59 patients (96.7%) in the aripiprazole group and 53 patients (88.3%) in the placebo group completed the study. The aripiprazole group showed significantly greater improvement in the YGTSS-TTS from baseline to week 8 than the placebo group (least squares mean difference [95% confidence interval (CI)] −5.5 [95% CI − 8.4 to − 2.6]). At week 8, the response rate (i.e., percentage of patients with a Tourette’s Syndrome Clinical Global Impression-Improvement score of 1 or 2) of the aripiprazole group (86.4%) was significantly higher than that of the placebo group (56.6%; odds ratio: 3.6, p < 0.001). The incidence of treatment-emergent adverse events (TEAEs) reported in at least one patient was 86.9% in the aripiprazole group and 65.5% in the placebo group. All TEAEs were mild or moderate in severity. No serious adverse events or deaths occurred during the study. Conclusions Our findings suggest that aripiprazole oral solution is an effective, well-tolerated, and safe treatment for children and adolescents with TD. Trial registration ClinicalTrials.gov Identifier: NCT03487783. Registered 4 April 2018.

Keywords